Anupam Rasayan Q4 & FY26 Results: Revenue Grows 65% to ₹23,836 Mn, PAT Up 39% to ₹2,222 Mn
Anupam Rasayan reported FY26 consolidated revenue of ₹23,836 Mn (up 65% YoY) and PAT of ₹2,222 Mn (up 39% YoY). Q4FY26 revenue was ₹6,358 Mn. Key highlights include the acquisition of Jayhawk Fine Chemicals and a definitive agreement to acquire a stake in Bliss GVS Pharma. The company achieved its highest-ever annual sales and operating cash flow.
The announcement includes significant financial performance improvements, strategic acquisitions, and positive future outlooks, which are material events for investors.
The company reported strong year-on-year growth in revenue and profit, along with achieving record sales and operating cash flow. Strategic acquisitions and expansion plans also contribute to a positive outlook.
Anupam Rasayan India Limited has announced its audited financial results for the fourth quarter and full financial year ended March 31, 2026. The company reported a significant increase in its top line, with total revenue growing by 65% year-on-year to ₹23,836 million for FY26. The Profit After Tax (PAT) also saw a substantial rise of 39% to ₹2,222 million for the full fiscal year.
For the fourth quarter of FY26, the consolidated revenue from operations stood at ₹6,358 million, a 23% increase compared to the same period last year. EBITDA for Q4FY26 was ₹1,407 million, showing a de-growth of 6% from Q4FY25. However, for the full fiscal year FY26, consolidated EBITDA grew by 32% to ₹5,430 million.
The company highlighted that FY26 was a landmark year, marked by strong operational execution and strategic expansion. Key achievements included the successful acquisition of Jayhawk Fine Chemicals in the United States, which contributed positively to the proforma performance. Jayhawk reported a revenue of US$76 million for the year. Additionally, Anupam Rasayan signed a definitive agreement to acquire a controlling stake in Bliss GVS Pharma, further strengthening its pharmaceutical value chain capabilities.
The company achieved its highest-ever annual sales of ₹23,836 million and operating cash flow of ₹3,343 million in FY26. This growth was driven by the commercialization of new products, the addition of new multinational customers, and expanding engagements across key business verticals. Anupam Rasayan is well-positioned for future growth, supported by increasing contributions from its Performance Materials and Pharmaceuticals segments.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.